{"id":"61a943f308a3","type":"article","url":"https://hartvaat.nl/2026/11/07/initieel-diabetesmedicatie-na-cabg-verlaagt-sterfte-en-hartfalen-heropnames-optu/","title":"Initieel diabetesmedicatie na CABG verlaagt sterfte en hartfalen-heropnames — OptumLabs-cohort","title_en":"Initial Diabetes Therapy After Coronary Artery Bypass Grafting and Long-Term Outcomes.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"Journal of the American Heart Association","doi":"10.1161/JAHA.126.053850","source_url":"https://doi.org/10.1161/JAHA.126.053850","authors":["Vincy Tam","Hartzell V Schaff","Viengneesee Thao","Holly Van Houten","Robert L Frye","Kevin L Greason","Yazan N AlJamal","Philip J Spencer","Philip G Rowse","Juan A Crestanello"],"significance":5,"published":"2026-11-16","source_date":"2026-11-07","image":"","kennis":[],"congress":"","summary_en":"In a retrospective cohort of 19,237 patients with type 2 diabetes undergoing isolated CABG, post-discharge initiation of glucose-lowering therapy was associated with significantly lower all-cause mortality compared with no therapy. Metformin (HR 0.60) and GLP-1RA/SGLT2i (HR 0.71) showed stronger mortality benefits than insulin (HR 0.75), while metformin also reduced heart failure hospitalizations and stroke incidence. These real-world findings highlight a postoperative care gap and suggest that early, guideline-directed diabetes therapy after surgical revascularization is a key opportunity to improve long-term cardiovascular outcomes.","created":"2026-11-09T02:36:38Z","updated":"2026-11-09T02:36:38Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"In een retrospectief cohort van 19.237 patiënten met type 2-diabetes na een CABG-operatie bleek initiële glucoseverlagende therapie geassocieerd met een lagere sterfte vergeleken met geen therapie. Metformin (HR 0,60) en GLP-1RA/SGLT2i (HR 0,71) waren beide effectiever dan insuline (HR 0,75), en metformin verlaagde ook het risico op hartfalen-heropnames en beroerten. Deze bevindingen benadrukken een zorgkloof in de postoperatieve diabeteszorg en suggereren dat vroegtijdige start van passende antidiabetica na CABG de langetermijnprognose aanzienlijk kan verbeteren.","abstract_original":"BACKGROUND: Type 2 diabetes (T2D) is common among patients undergoing coronary artery bypass grafting (CABG), but optimal post-CABG glucose-lowering therapy remains uncertain. METHODS: We conducted a retrospective cohort study using the OptumLabs Data Warehouse of adults with T2D undergoing isolated CABG from 2012-2024. Follow-up began 30 days after discharge. Glucose-lowering therapy was modeled as a time-varying exposure with patients contributing no-observed-therapy person-time until the first qualifying post-discharge fill. Pairwise comparisons used stabilized inverse probability of treatment weighting. The primary outcome was all-cause mortality; secondary outcomes were heart failure hospitalization, stroke, and repeat coronary revascularization. RESULTS: Among 19,237 patients, 24.9% had no observed post-discharge therapy, 42.8% received metformin, 22.9% received insulin, and 9.4% received GLP-1RA/SGLT2i therapy. All active therapies were associated with lower mortality compared with no observed therapy, including GLP-1RA/SGLT2i (HR 0.71, 95% CI 0.58-0.87), metformin (HR 0.60, 95% CI 0.55-0.66), and insulin (HR 0.75, 95% CI 0.67-0.84). Among active therapies, metformin was associated with lower mortality than insulin (HR, 0.61 [0.54-0.70]); GLP-1RA/SGLT2i comparisons with metformin and insulin were less precise. Metformin was also associated with lower cumulative incidence of heart failure hospitalization than no observed therapy and insulin, and lower stroke incidence than insulin. CONCLUSIONS: Observed glucose-lowering therapy initiation after CABG was associated with lower mortality compared with no observed therapy across all active treatment groups. These findings highlight a potential care gap and suggest that proper initiation of diabetes therapy after CABG represents an important opportunity to improve long-term outcomes following surgical revascularization."}